This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Galapagos NV

Drug Names(s): GLPG0555

Description: GLPG055 is an orally-available, novel drug that modifies kinase target GT622 and was identified through Galapagos' proprietary target discovery platform. GT622 is thought to be involved in cartilage repair, including up-regulation of twocartilagenous matrix components, collagen II and the proteoglycan aggrecan.

Deal Structure: Galapagos and GlaxoSmithKline
In June 2006, GlaxoSmithKline (GSK) and Galapagos initiated an arthritis alliance to discover and develop disease-modifying drugs for GSK's global R&D organization.

The aim of this agreement is for Galapagos to expand its portfolio of novel validated targets in the field of osteoarthritis, to conduct compound screening, identify tractable hits, pursue a number of hit-to-lead programmes, and develop the resulting leads into candidate selection compounds through to a successful Proof of Concept in clinical research Phase IIa. GSK will have exclusive options to further develop and commercialise these compounds on a worldwide basis. Galapagos will have the right to further develop and commercialise compounds for which GSK does not exercise its option.

Under the terms of the agreement, Galapagos will receive an upfront technology access fee of EUR 4 million from GSK. Upon successful completion of all agreed alliance programme criteria,...See full deal structure in Biomedtracker

Partners: GlaxoSmithKline plc

GLPG0555 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug